Skip to content

News

OCRFA Funded Study Looks at the Link Between Hypertension a...

OCRFA Funded Study Looks at the Link Between Hypertension and Ovarian Cancer

(April 25, 2017) Researchers from Roswell Park Cancer Institute used data from 15 different studies that were part of the Ovarian Cancer Association Consortium, partially funded by OCRFA, to examine the relationship between epithelial ovarian cancer and hypertension, heart disease, diabetes, and the medications associated with those diseases. After reviewing over 7,600 cases, it was … Continued

OCRFA Research Finds New Genetic Variants Linked to Ovarian...

OCRFA Research Finds New Genetic Variants Linked to Ovarian Cancer

A study published in Nature Genetics has identified nine new susceptibility loci, or disease-associated alleles, for different epithelial ovarian cancer (EOC) histotypes and three susceptibility loci within BRCA1 and 2 mutation carriers with EOC. Researchers, including former OCRFA grantee and current OCRFA Scientific Advisory Committee Member Andrew Berchuck, looked at data from 25,509 EOC cases … Continued

Hormone Therapy Improves Survival of Low Grade Serous Carci...

Hormone Therapy Improves Survival of Low Grade Serous Carcinoma Patients

(March 6, 2017) A team from University of Texas MD Anderson Cancer Center, including OCRFA Scientific Advisory Committee Member Dr. Robert Coleman, published a study in Journal of Clinical Oncology about the effect of hormonal therapy on a rare type of ovarian cancer. The use of hormone maintenance therapy (HMT) with low-grade serous carcinoma (LGSC), … Continued

OCRFA Research Finds New Gene Mutation Spurs Cancer Growth

OCRFA Research Finds New Gene Mutation Spurs Cancer Growth

(February 7, 2017) An OCRFA funded study, published on January 13, 2017 in Oncotarget, sheds light on EMSY, a gene that researchers at New York University Langone Medical Center now understand to have a role similar to those of BRCA1 and BRCA2. BRCA1 and BRCA2 are well known genes that, when working, help with DNA … Continued

Rucaparib Extends PFS in Ovarian Cancer

Rucaparib Extends PFS in Ovarian Cancer

(February 3, 2017) Results from the ARIEL2 trial, funded in part by OCRFA’s grant to the Stand Up to Cancer Ovarian Cancer Dream Team, were recently published in The Lancet. The goal of the trial was to test if the efficacy of rucaparib, an oral PARP inhibitor, was dependent on the type of tumor mutation. … Continued

OCRFA Funded Research Studies DNA Repair in Ovarian Cancer ...

OCRFA Funded Research Studies DNA Repair in Ovarian Cancer Cells

(January 30, 2017) In a study funded in part by OCRFA, and published this month in Oncotarget, researchers, including first author and former OCRFA grantee Petar Jelinic, PhD, studied EMSY, a putative BRCAness gene, and its role in the suppression of DNA damage repair in ovarian cancer cells. The EMSY gene is amplified in approximately … Continued

OCRFA Awards $5.6 Million in Scientific Research Grants for...

OCRFA Awards $5.6 Million in Scientific Research Grants for 2017

(January 20, 2017) OCRFA has awarded $5.6 million in new scientific research grants for ovarian cancer, bringing our total investment in life-saving research to over $75 million. This year’s grants have been awarded to twenty top scientists at thirteen leading medical centers across the country. “Our 2017 grantees are among the best and brightest working … Continued

Now Accepting Applications for 2017 Community Partners

Now Accepting Applications for 2017 Community Partners

OCRFA’s Community Partners (formerly called Partner Members) are outstanding grassroots, local and national organizations around the country who share a commitment to eradicate ovarian cancer through research, advocacy, support, education and awareness. The goal of our Community Partners initiative is to unite the ovarian cancer community into a national movement speaking with one voice through … Continued

Give today to invest in tomorrow’s cure.

Give today to invest in tomorrow’s cure.

Time is running out to make your tax-deductible 2016 gift to OCRFA. We need your help. Over 22,000 women will be diagnosed with ovarian cancer in 2017. Over 200,000 women are currently living with ovarian cancer. Your support will make a big difference in the lives of these women and their families. Ovarian cancer is … Continued

Fighting Ovarian Cancer Through Patient Support and Education

Fighting Ovarian Cancer Through Patient Support and Education

Every year, 22,000 women are newly diagnosed with ovarian cancer. As OCRFA strives toward a cure and better treatments through research, we also provide patients and survivors with the care they need through our support and education programs. Now in 29 sites across the country, our Woman to Woman program has impacted over 400 women, … Continued

Federal Funding for Ovarian Cancer: 2016 Highlights

Federal Funding for Ovarian Cancer: 2016 Highlights

As the voice for women with ovarian cancer on Capitol Hill, OCRFA fights to secure funding for ovarian cancer research and education at the federal level. In 2016, with the help of committed Advocate Leaders, Grassroots Advocates, Research Advocates and action alert supporters, OCRFA was able to: We’ve made great strides in ensuring that ovarian … Continued

Five Important Discoveries from OCRFA-Funded Researchers in...

Five Important Discoveries from OCRFA-Funded Researchers in 2016

OCRFA-funded scientists are working hard to save women’s lives. In medical institutions across the country, they investigate the origins and biology of ovarian cancer, find new ways to identify and prevent the disease, and discover better treatments. In 2016, our grantees made significant advances in the fight against ovarian cancer, including: Progress is being made … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.